BioMarin Pharmaceutical Inc.

Filing receipts

“Interest Expense for the periods presented was as follows: Three Months Ended March 31, 2026 2025 Change Interest expense $ 15.0 $ 2.9 $ 12.1 The increase in Interest Expense for the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 was primarily due to issuance of 2034 Notes for $850.0 million aggregate principal in February 2026, and $5.3 million of bridge commitment fees recognized during the three months ended March 31, 2026.”

“The following table shows our Net Product Revenues denominated in USD and foreign currencies: Three Months Ended March 31, 2026 2025 Change Sales denominated in USD $ 362.7 $ 358.3 $ 4.4 Sales denominated in foreign currencies 397.4 376.3 21.1 Total net product revenues $ 760.1 $ 734.6 $ 25.5 Three Months Ended March 31, 2026 2025 Change Favorable (unfavorable) impact of foreign currency exchange rates on product sales denominated in currencies other than USD $ 8.6 $ (13.6) $ 22.2 The favorable impact for the three months ended March 31, 2026 was primarily driven by strengthening of the Euro and Mexican Peso, partially offset by weakening of the Argentine Peso and the Japanese Yen.”

“23 Table of Contents Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued) (In millions of U.S. dollars, except as otherwise disclosed) The following table summarizes our Cost of Sales and Gross Margin: Three Months Ended March 31, 2026 2025 Change Total revenues $ 766.2 $ 745.1 $ 21.1 Cost of sales $ 195.0 $ 151.6 $ 43.4 Gross margin 74.5 % 79.7 % (5.2) % Cost of Sales increased and Gross Margin decreased in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025, primarily due to a $31.0 million charge associated with an unsuccessful process qualification campaign to expand NAGLAZYME manufacturing capabilities.”